Search

Displaying results 5021 - 5030 of 10000 in total
  1. Drug

    ORM-13070 C-11

    go.drugbank.com/drugs/DB15324
    Investigational

    ORM-13070 C-11 is under investigation in clinical trial NCT00735774 (Suitability of 11C-ORM-13070 as a PET Tracer).

  2. Drug

    Gatipotuzumab

    go.drugbank.com/drugs/DB18861
    Investigational

    Gatipotuzumab is under investigation in clinical trial NCT01899599 (Pankomab-gex™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer).

  3. Drug

    ORE-1001

    go.drugbank.com/drugs/DB12271
    Investigational

    It is an ACE2 inhibitor.

  4. Drug

    MC-1

    go.drugbank.com/drugs/DB05315
    Experimental

    Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

  5. Drug

    PB127

    go.drugbank.com/drugs/DB06208
    Investigational

  6. Drug

    N,N,N-trimethylglycinium

    go.drugbank.com/drugs/DB04455
    Investigational

    As a drug, betaine hydrochloride has been used as a source of hydrochloric acid in the treatment of hypochlorhydria. … A naturally occurring compound that has been of interest for its role in osmoregulation.

  7. Drug

    Amsilarotene

    go.drugbank.com/drugs/DB21085
    Investigational

    Amsilarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Amsilarotene is a arotinoid derivative. … Amsilarotene has a monoisotopic molecular weight of 385.15 Da.

  8. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors. … GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline

  9. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    history of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a

  10. Drug

    S-40503

    go.drugbank.com/drugs/DB13938
    Experimental

    S-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.